New York State Psychiatric Institute: Psychotic Disorders trials

The registry lists 27 Psychotic Disorders studies with New York State Psychiatric Institute as lead sponsor. 5 are open to participants now and 13 have results posted.

Early Phase 1 1Phase 1 5Phase 2 5Phase 3 2Phase 4 6No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in SchizophreniaNot yet recruitingNCT07715253Phase 1
• Exercise and Olanzapine-samidorphanRecruitingNCT06740890Phase 4
• Treating Common Mental Disorders in Women in Mozambique by Addressing Intimate Partner Violence in CouplesNot yet recruitingNCT06252909Not applicable
• Shared Decision Making for Antipsychotic MedicationsNot yet recruitingNCT05416658Not applicable
• Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical TrialRecruitingNCT05208190Phase 4
• D-serine Augmentation of NeuroplasticityCompletedNCT03711500Phase 1/2Results posted
• Improving Accessibility and Personalization of CR for SchizophreniaCompletedNCT03576976Not applicableResults posted
• Remediation of Auditory Recognition in Schizophrenia With tDCSCompletedNCT02869334Not applicableResults posted
• Comparative Effectiveness of Adaptive Treatment Strategies for SchizophreniaCompletedNCT02775864Results posted
• Treatment of Psychosis and Agitation in Alzheimer's DiseaseCompletedNCT02129348Phase 2Results posted
• Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of SchizophreniaCompletedNCT02034474Phase 4Results posted
• Personalized and Scalable Cognitive Remediation ApproachesCompletedNCT01945333Not applicableResults posted
• Kuvan in People With Schizophrenia and Schizoaffective DisorderCompletedNCT01706965Phase 1/2Results posted
• Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on LurasidoneCompletedNCT01173874Phase 3Results posted
• A Comparison of Long-acting Injectable Medications for SchizophreniaCompletedNCT01136772Phase 4Results posted
• Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)TerminatedNCT00517075Phase 2Results posted
• Open-label Ziprasidone Study for Psychosis Treatment in AdolescentsCompletedNCT00421954Phase 3Results posted
• Antipsychotic Discontinuation in Alzheimer's DiseaseCompletedNCT00417482Phase 4Results posted
• D-serine AudRem: R33 PhaseSuspendedNCT05046353Phase 1/2
• OnTrackNY's Learning Healthcare SystemSuspendedNCT04021719
• Cognitive Remediation for Coordinated Specialty CareSuspendedNCT03930251Not applicable
• Clinical Trial of AVL-3288 in Schizophrenia PatientsCompletedNCT02978599Phase 1
• Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric DisordersCompletedNCT01519557Early Phase 1
• Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral TherapyCompletedNCT00791440Not applicable
• Critical Time Intervention in the Transition From Hospital to Community in People With Severe Mental IllnessCompletedNCT00621465Not applicable
• Enhancing the Outcome of Skills Training for People With SchizophreniaCompletedNCT00069433Not applicable
• Treatment of Behavioral Symptoms in Alzheimer's DiseaseCompletedNCT00009217Phase 4